您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2018, Vol. 56 ›› Issue (5): 13-17.doi: 10.6040/j.issn.1671-7554.0.2018.220

• • 上一篇    下一篇

早期上皮性卵巢癌保留生育功能手术患者预后与妊娠状况的影响因素

张颖1,杨佳欣1,曹冬焱1,俞梅1,沈铿1,黄惠芳1,潘凌亚1,吴鸣1,郎景和1,游燕2   

  1. 中国医学科学院北京协和医学院 北京协和医院 1.妇产科;2.病理科, 北京 100730
  • 收稿日期:2018-02-12 发布日期:2022-09-27
  • 通讯作者: 杨佳欣. E-mail:YangJiaXin@pumch.cn
  • 基金资助:
    国家科技部十一五国家科技支撑计划(2008BAI57B02)

Prognostic factors for oncology and fertility outcomes of early stage epithelial ovarian cancer patients who accepted fertility-sparing surgery

ZHANG Ying1, YANG Jiaxin1, CAO Dongyan1, YU Mei1, SHEN Keng1, HUANG Huifang1, PAN Lingya1, WU Ming1, LANG Jinghe1, YOU Yan2   

  1. 1. Department of Obstetrics and Gynecology;
    2. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &
    Peking Union Medical College, Beijing 100730, China
  • Received:2018-02-12 Published:2022-09-27

PDF (PC)

202

摘要： 目的 探讨保留生育功能手术(FSS)治疗早期上皮性卵巢癌(EOC)的可行性及影响患者预后和生育状况的因素。 方法 回顾性分析接受FSS治疗的EOC患者38例,记录年龄、初次手术方式、病理类型、组织学分级、临床分期及初治后是否化疗等可能影响因素,对其术后生存、复发及妊娠生育情况进行分析。 结果 中位随访时间90.5个月。5年总体生存率97%,5年无进展生存率80%。随访期间复发率28.9%。组织学分级(G2/G3)是影响无进展生存期的惟一独立危险因素(χ2=39.36, P<0.001);ⅠA期和ⅠC1/ⅠC2期患者的总体生存率及无进展生存率差异无统计学意义(P>0.05);治疗后有生育条件的患者妊娠率为62.5%,活产率40.6%。术后妊娠率不受年龄、手术方式、临床分期、初治后是否化疗和是否复发等因素影响。 结论 FSS可用于早期EOC患者,其总体肿瘤预后及妊娠状况较好,组织学分级是影响生存及复发的高危因素。

关键词: 上皮性卵巢癌, 保留生育功能, 手术, 预后因素, 生育状况

Abstract: Objective To investigate the influencing factors of tumor and fertility prognosis for patients with early stage epithelial ovarian cancer(EOC)who accepted fertility-sparing surgery(FSS). Methods A retrospective study was done on the clinical data of 38 patients with EOC who had undergone FSS to assess the influencing factors such as age, surgery, pathological type, histological grade, clinical stage, or chemotherapy after the surgery, on the clinical and fertility outcomes. Results The median time of follow-up was 90.5 months. The 5-year overall survival(OS)rate and 5-year progression-free survival(PFS)rate was 97% and 80%, respectively, while the rate of relapse was 28.9%. Only grade G2/G3 influenced PFS significantly(χ2=39.36, P<0.001). No significant difference was found between stage ⅠA and ⅠC1/ⅠC2(P>0.05). The conception rate was 62.5%, and 40.6% of the patients had live birth. Fertility outcomes were not influenced by age, surgery, FIGO stage, chemotherapy or relapse. Conclusion Conservative treatment for early EOC patients can be performed reasonably because of the good outcomes of tumor and fertility prognosis. Histological grade is risk factor that should be considered for the patients’ treatment.

Key words: Epithelial ovarian cancer, Fertility-sparing, Surgery, Prognosis factors, Fertility outcome

中图分类号: 

  • R737.31
[1] Park B, Park S, Kim TJ, et al. Epidemiological characteristics of ovarian cancer in Korea[J]. J Gynecol Oncol, 2010, 21(4): 241-247.
[2] Plaxe SC, Braly PS, Freddo JL, et al. Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer[J]. Obstet Gynecol, 1993, 81(5): 651-654.
[3] Duska LR, Chang YC, Flynn CE, et al. Epithelial ovarian carcinoma in the reproductive age group[J]. Cancer, 1999, 85(12): 2623-2629.
[4] Smedley H, Sikora K. Age as prognostic factor in epithelial ovarian carcinoma[J]. Br J Obstet Gynaecol, 1985, 92(8): 839-842.
[5] Kashima K, Yahata T, Fujita K, et al. Outcomes of fertility-sparing surgery for women of reproductive age with FIGO stage IC epithelial ovarian cancer[J]. Int J Gynaecol Obstet, 2013, 121(1): 53-55.
[6] Melamed A, Rizzo AE, Nitecki R, et al. All-cause mortality after fertility-sparing surgery for stage I epithelial ovarian cancer[J]. Obstet Gynecol, 2017, 130(1): 71-79.
[7] Kajiyama H, Mizuno M, Shibata K, et al. Recurrence-predicting prognostic factors for patients with early-stage epithelial ovarian cancer undergoing fertility-sparing surgery: a multi-institutional study[J]. Eur J Obstet and Gynecol Reprod Biol, 2014, 175(1): 97-102.
[8] Zapadiel I, Diestro MD, Aletti G. Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes[J]. Eur J Surg Oncol, 2014, 40(4): 387-393.
[9] Fruscio R, Corso S, Ceppi L, et al. Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series[J]. Ann Oncol, 2013, 24(5): 138-144.
[10] Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer[J]. JAMA, 1983, 250(22): 3072-3076.
[11] Hillman RT, Saenz CC, McHale MT, et al. Fertility preservation and survival among young women with early ovarian cancer living in US counties with gynecologic oncologist services[J]. Int J Gynaecol Obstet, 2017, 137(2): 157-163.
[12] Bentivegna E, Gouy S, Maulard A, et al. Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues[J]. Ann Oncol, 2016, 27(11): 1994-2004.
[13] American College of Obstetrics and Gynecologists. ACOG practice bulletin. Management of adnexal mass[J]. Obstet Gynecol, 2007, 110(4): 201-214.
[14] Kajiyama H, Shibata K, Mizuno M, et al. Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery[J]. Br J Cancer, 2011, 105(9): 1288-1294.
[15] Ditto A, Marinelli F, Bogani G, et al. Long-term safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures[J]. Gynecol oncol, 2015, 138(1): 78-82.
[16] Fruscio R, Ceppi L, Corso S, et al. Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer[J]. Br J Cancer, 2016, 115(6): 641-648.
[17] Mirabeau-Beale KL, Kornblith AB, Penson RT, et al. Comparison of the quality of life of early and advanced stage ovarian cancer survivors[J]. Gynecol Oncol, 2009, 114(2): 353-359.
[18] Power L, Lefas G, Lambert P, et al. Hormone use after nonserous epithelial ovarian cancer: overall and disease-free survival[J]. Obstet Gynecol, 2016, 127(5): 837-841.
[1] 徐宁宇 王磊 郝恩魁 苏国海. STEMI患者急诊PCI前口服阿托伐他汀对炎症介质及左心室功能的影响[J]. 山东大学学报(医学版), 2209, 47(6): 69-72.
[2] 张小艳 李刚 王令平. 不同剂量舒芬太尼对脊柱手术患者全麻诱导期血流动力学及血浆皮质醇的影响[J]. 山东大学学报(医学版), 2209, 47(6): 76-79.
[3] 梁晨,姚丽娟,吕龙飞,唐泽,秦达,崔有斌,余孝淇. 三维重建联合CT引导下穿刺定位在微创治疗肺磨玻璃结节中的应用[J]. 山东大学学报 (医学版), 2026, 64(5): 74-82.
[4] 王烨,王刚,南海鸥,蔡雨玲,李嘉宇,王海锋,颜英杰,江志伟. 胃癌患者围手术期心率变异度与炎性指标的相关性[J]. 山东大学学报 (医学版), 2026, 64(4): 23-30.
[5] 周志远,石玉心,顾赫泽,侯奕阳,徐欣. 正颌手术对严重骨性Ⅲ 类患者上气道大小的影响及关键因素筛选[J]. 山东大学学报 (医学版), 2026, 64(4): 44-50.
[6] 机器人辅助经椎间孔腰椎椎体间融合术手术技术专家组. 机器人辅助经椎间孔腰椎椎体间融合术专家共识[J]. 山东大学学报 (医学版), 2026, 64(2): 11-21.
[7] 邵长秀,贺青卿,王宇男,宋泽辉,岳涛,周鹏,李小磊,庄大勇. 改良腋窝单孔非溶脂腔镜腺体切除治疗男性乳房发育症的学习曲线与疗效评估[J]. 山东大学学报 (医学版), 2026, 64(1): 109-117.
[8] 张蕾,潘叶,李家根,赵红. Hughes改良瓣修复大面积下睑全层缺损的临床效果[J]. 山东大学学报 (医学版), 2025, 63(7): 37-43.
[9] 温学龙,刘安慧,陈经纬,吴梦婷,杨岷. 急性非ST抬高型心肌梗死行冠状动脉旁路移植手术时机Meta分析[J]. 山东大学学报 (医学版), 2025, 63(5): 60-70.
[10] 王宝炫,焦杰,张厚君,刘奇,于冠英. 衰弱与肌少症评估在胃肠道肿瘤术后结局预测中的应用与展望[J]. 山东大学学报 (医学版), 2025, 63(4): 51-58.
[11] 张翼翔,梁原浩,杨文龙,李国强,吴文庆,刘垒. 基于术中C臂X光图像骨性标识的椎间孔镜手术路径构建[J]. 山东大学学报 (医学版), 2025, 63(3): 14-21.
[12] 山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报 (医学版), 2025, 63(12): 1-5.
[13] 丁仰坤,刘涛,刘宇,于嘉智,牟鹏飞. 金黄色葡萄球菌致儿童急性血源性骨髓炎首次术后细菌转阴的影响因素[J]. 山东大学学报 (医学版), 2025, 63(12): 53-60.
[14] 黄艳,周应芳,彭超. 青少年子宫内膜异位症的管理要点和策略[J]. 山东大学学报 (医学版), 2025, 63(10): 8-12.
[15] 王伦常,覃淇,舒畅. 创伤性B型主动脉夹层的诊疗进展[J]. 山东大学学报 (医学版), 2024, 62(9): 19-25.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发